Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Cytometry. Part a : the Journal of the International Society for Analytical Cytology
|
April 2, 2021
Basophil activation test: Assay precision and BI 1002494 SYK inhibition in healthy and mild asthmatics
Saskia Carstensen, Ewald Benediktus, Tobias Litzenburger, et al.
Mabs
|
June 6, 2015
Structure-guided residence time optimization of a dabigatran reversal agent
Felix Schiele, Joanne van Ryn, Tobias Litzenburger, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 27, 2025
Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis
Shervin Assassi, Christopher P Denton, Matthias Zwick, et al.
Blood
|
March 12, 2013
A specific antidote for dabigatran: functional and structural characterization
Felix Schiele, Joanne van Ryn, Keith Canada, et al.
Scientific Reports
|
January 19, 2024
Transcriptomic characterization of the human segmental endotoxin challenge model
Christina Gress, Tobias Litzenburger, Ramona Schmid, et al.
British Journal of Pharmacology
|
February 7, 2026
Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma
Saskia Carstensen-Aurèche, Tobias Litzenburger, Dorothy De Sousa, et al.
Mabs
|
March 12, 2015
Boosting antibody developability through rational sequence optimization
Daniel Seeliger, Patrick Schulz, Tobias Litzenburger, et al.
Pulmonary Pharmacology & Therapeutics
|
August 10, 2023
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers
Christina Gress, Jens Vogel-Claussen, Philipp Badorrek, et al.
Human Antibodies
|
December 2, 2011
Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity
Patricia Giblin, Rainer Boxhammer, Sudha Desai, et al.
British Journal of Clinical Pharmacology
|
September 28, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
Tobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Cytometry. Part a : the Journal of the International Society for Analytical Cytology
|
April 2, 2021
Basophil activation test: Assay precision and BI 1002494 SYK inhibition in healthy and mild asthmatics
Saskia Carstensen, Ewald Benediktus, Tobias Litzenburger, et al.
Mabs
|
June 6, 2015
Structure-guided residence time optimization of a dabigatran reversal agent
Felix Schiele, Joanne van Ryn, Tobias Litzenburger, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
May 27, 2025
Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Course of Interstitial Lung Disease in Patients With Systemic Sclerosis
Shervin Assassi, Christopher P Denton, Matthias Zwick, et al.
Blood
|
March 12, 2013
A specific antidote for dabigatran: functional and structural characterization
Felix Schiele, Joanne van Ryn, Keith Canada, et al.
Scientific Reports
|
January 19, 2024
Transcriptomic characterization of the human segmental endotoxin challenge model
Christina Gress, Tobias Litzenburger, Ramona Schmid, et al.
British Journal of Pharmacology
|
February 7, 2026
Safety, tolerability, pharmacokinetics and pharmacodynamics of the spleen tyrosine kinase inhibitor BI 894416 in healthy volunteers and patients with asthma
Saskia Carstensen-Aurèche, Tobias Litzenburger, Dorothy De Sousa, et al.
Mabs
|
March 12, 2015
Boosting antibody developability through rational sequence optimization
Daniel Seeliger, Patrick Schulz, Tobias Litzenburger, et al.
Pulmonary Pharmacology & Therapeutics
|
August 10, 2023
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers
Christina Gress, Jens Vogel-Claussen, Philipp Badorrek, et al.
Human Antibodies
|
December 2, 2011
Fully human antibodies against the Protease-Activated Receptor-2 (PAR-2) with anti-inflammatory activity
Patricia Giblin, Rainer Boxhammer, Sudha Desai, et al.
British Journal of Clinical Pharmacology
|
September 28, 2020
Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers
Tobias Litzenburger, Jürgen Steffgen, Ewald Benediktus, et al.
Page
of 2